Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Interest ReceivablesChange in ReceivablesChange in Working CapitalDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abivax (ABVX) Change in Account Payables: 2024-2025

  • Abivax's Change in Account Payables rose 104.60% to $1.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$4.0 million, marking a year-over-year change of. This contributed to the annual value of -$3.7 million for FY2024, which is 110.77% down from last year.
  • According to the latest figures from Q2 2025, Abivax's Change in Account Payables is $1.1 million, which was down 91.70% from $13.4 million recorded in Q1 2025.
  • Abivax's Change in Account Payables' 5-year high stood at $13.4 million during Q1 2025, with a 5-year trough of -$24.2 million in Q2 2024.
  • In the last 2 years, Abivax's Change in Account Payables had a median value of $3.4 million in 2024 and averaged -$1.0 million.
  • Data for Abivax's Change in Account Payables shows a peak YoY surged of 137.53% (in 2025) over the last 5 years.
  • Over the past 2 years, Abivax's Change in Account Payables (Quarterly) stood at -$24.2 million in 2024, then soared by 104.60% to $1.1 million in 2025.
  • Its last three reported values are $1.1 million in Q2 2025, $13.4 million for Q1 2025, and -$24.2 million during Q2 2024.